Tech Company Inital Public Offerings
Editas Medicine IPO
Editas Medicine was acquired by . Shares were listed on 2/2/2016.
Transaction Overview
Company Name
Announced On
2/2/2016
Transaction Type
IPO
Amount
$94,400,000
Proceeds Purpose
We intend to use approximately $15 to $20 million of the net proceeds from this offering for preclinical studies and clinical trials for our LCA10 program and up to $22 million of the net proceeds from this offering for preclinical studies in our collaboration with Juno Therapeutics. We intend to use the remainder of the net proceeds from this offering for continued expansion of our platform technology, preclinical studies of our research programs in addition to LCA10 and engineered T cells, working capital and general corporate purposes. We believe opportunities may exist from time to time to expand our current business through acquisitions of complementary companies, products, or technologies.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
11 Hurley St.
Cambridge, MA 02141
USA
Cambridge, MA 02141
USA
Phone
Website
Email Address
Overview
Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Cynthia Collins
Chief Medical Officer
Judith Abrams
Chief Scientific Officer
Charles Albright
VP - Operations
Harry Gill
VP - Regulatory Affairs
Timothy Hunt
Browse more venture capital transactions:
Prev: 2/2/2016: DisperSol Technologies venture capital transaction
Next: 2/2/2016: LimitScreen venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs